Conducting clinical trials during the COVID-19 pandemic—a collaborative trial network response

Laura Robison; Yeoungjee Cho; Andrea K. Viecelli; David W. Johnson; Carmel M. Hawley; Andrea Valks; Peta-Anne Paul-Brent; Ruth Stastny; Julie Varghese; Charani Kiriwandeniya; Elaine M. Pascoe; Liza A. Vergara; Magid A. Fahim; Neil Boudville; Rathika Krishnasamy; Donna Reidlinger; on behalf of the Australasian Kidney Trials Network

doi:10.1186/s13063-021-05200-0

Trials (Apr 2021)

Conducting clinical trials during the COVID-19 pandemic—a collaborative trial network response

Laura Robison,
Yeoungjee Cho,
Andrea K. Viecelli,
David W. Johnson,
Carmel M. Hawley,
Andrea Valks,
Peta-Anne Paul-Brent,
Ruth Stastny,
Julie Varghese,
Charani Kiriwandeniya,
Elaine M. Pascoe,
Liza A. Vergara,
Magid A. Fahim,
Neil Boudville,
Rathika Krishnasamy,
Donna Reidlinger,
on behalf of the Australasian Kidney Trials Network

Affiliations

Laura Robison: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Yeoungjee Cho: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Andrea K. Viecelli: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
David W. Johnson: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Carmel M. Hawley: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Andrea Valks: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Peta-Anne Paul-Brent: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Ruth Stastny: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Julie Varghese: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Charani Kiriwandeniya: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Elaine M. Pascoe: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Liza A. Vergara: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Magid A. Fahim: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Neil Boudville: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Rathika Krishnasamy: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Donna Reidlinger: Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
on behalf of the Australasian Kidney Trials Network

DOI: https://doi.org/10.1186/s13063-021-05200-0
Journal volume & issue: Vol. 22, no. 1
pp. 1 – 9

Abstract

Read online

Abstract The unprecedented demand placed on healthcare systems from the COVID-19 pandemic has forced a reassessment of clinical trial conduct and feasibility. Consequently, the Australasian Kidney Trials Network (AKTN), an established collaborative research group known for conducting investigator-initiated global clinical trials, had to efficiently respond and adapt to the changing landscape during COVID-19. Key priorities included ensuring patient and staff safety, trial integrity and network sustainability for the kidney care community. New resources have been developed to enable a structured review and contingency plan of trial activities during the pandemic and beyond.

Published in Trials

ISSN: 1745-6215 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General)
Website: https://trialsjournal.biomedcentral.com

About the journal